BioCryst Secures Approval for ORLADEYO in Pediatric Hereditary Angioedema Patients in Japan

The pharmaceutical company announced that its treatment ORLADEYO has received regulatory approval in Japan specifically for managing hereditary angioedema in pediatric populations.